Fall 2010 - Innovation

Low-Dose Polio Vaccine Effective

Giving just one-fifth the usual dose of the polio vaccine may protect babies against the virus nearly as well as a full dose, as long as it is injected just beneath the skin, according to a recent study. The study tested a needle-free jet injector made by Bioject Medical Technologies to deliver the vaccine beneath the skin in 373 children at ages 2 months, 4 months and 6 months. Blood tests showed that more than 95 percent of the infants mounted an effective immune response against polio. And, while babies who got a lower dose had fewer antibodies against polio, researchers said that shouldn’t be a problem.

The findings could reduce the cost of immunization, an important consideration in developing countries, some of which have had trouble containing the paralytic disease. The injectable vaccine costs about $3 per dose, whereas the oral polio vaccine is much cheaper, at about 15 cents, but it contains a weakened virus that can mutate and sometimes cause polio in patients or when it gets into sewage. Therefore, health experts now favor the injectable vaccine. “If we can do one-fifth the dose, we can at least get it down to $1, so we are getting into the neighborhood of a price that may be affordable for developing countries in the future,” says Dr. Roland Sutter of the World Health Organization.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.